Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $12.75 Average PT from Analysts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) has been assigned an average recommendation of "Hold" from the seven analysts that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $12.75.

MRNS has been the topic of a number of research analyst reports. StockNews.com downgraded Marinus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, August 22nd. Truist Financial reiterated a "buy" rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Wednesday, August 14th.

Marinus Pharmaceuticals Trading Down 2.1 %

NASDAQ:MRNS traded down $0.03 during mid-day trading on Thursday, reaching $1.39. 135,953 shares of the company's stock traded hands, compared to its average volume of 1,162,238. Marinus Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $11.26. The firm has a market capitalization of $76.36 million, a price-to-earnings ratio of -0.53 and a beta of 1.13. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The company has a 50 day moving average price of $1.32 and a 200-day moving average price of $3.52.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The business had revenue of $8.06 million for the quarter, compared to analysts' expectations of $9.05 million. During the same quarter in the prior year, the firm earned ($0.61) EPS. On average, sell-side analysts predict that Marinus Pharmaceuticals will post -1.88 earnings per share for the current year.

Institutional Trading of Marinus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Hussman Strategic Advisors Inc. lifted its position in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company's stock valued at $98,000 after acquiring an additional 10,500 shares in the last quarter. AQR Capital Management LLC lifted its position in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company's stock valued at $37,000 after acquiring an additional 12,934 shares in the last quarter. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals in the 2nd quarter valued at approximately $28,000. SG Americas Securities LLC bought a new position in Marinus Pharmaceuticals in the 2nd quarter valued at approximately $34,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in Marinus Pharmaceuticals in the 1st quarter valued at approximately $384,000. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.